Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Ovid Therapeutics Inc.NASDAQ: OVID
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 345.0% from a year ago
Cash & equivalents stood at $94.06M at the end of Q1 FY2026, up 345.0% from a year earlier and up 615.2% from the prior quarter. Over 3 fiscal years it compounded at -33.6% a year.
Context
- Cash & equivalents amounted to 41.7% of total assets at the end of Q1 FY2026, up 15.8 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +345.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 13.15M USD
- Year-over-year change
- -50.0%
- 4-year CAGR
- -48.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.15M | -50.0% |
| FY2024 | 2024-12-31 | 26.3M | -2.7% |
| FY2023 | 2023-12-31 | 27.04M | -39.7% |
| FY2022 | 2022-12-31 | 44.87M | -76.1% |
| FY2021 | 2021-12-31 | 187.8M | — |
Cash & Equivalents vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's Mar 2026 cash & equivalents of $94.06M is the 6th highest of the 11 companies compared; the peer median is $97.96M.
- Its year-over-year change of +345.0% is the highest of 11, against a peer median of +41.7%.
- Cash & equivalents amounts to 41.7% of total assets for OVID, versus a peer median of 30.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $544.59M | +124.0% | +89.5% | 93.3% | |
| Jun 2026 | $455.41M | +45.6% | +53.8% | 96.8% | |
| Mar 2026 | $175M | +37.7% | +48.3% | 13.5% | |
| Mar 2026 | $155.66M | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | $124.16M | +75.4% | +8.2% | 47.2% | |
| Mar 2026 | $94.06M | +345.0% | -33.6% | 41.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $71.54M | +7.5% | -17.1% | 29.2% | |
| Mar 2026 | $61.37M | +285.1% | +76.7% | 30.9% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
| Mar 2026 | $43.31M | -42.1% | -12.9% | 19.7% | |
| Peer median (excluding OVID) | $97.96M | +41.7% | +0.8% | 30.1% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M |
| Short-term Investments | 0 | 84.13M | 78.79M | 26.77M | 56.48M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.68M | 1 | 1K | 0 | 20.81M |
| Total Current Assets | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M |
| Property, Plant & Equipment (Net) | 242.76K | 16.07M | 14.66M | 13.23M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 164K | 222.1K | 200K | 92K | 0 |
| Long-term Investments | 3.56M | 5.62M | 17.63M | 20.97M | 64.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 96.13K | 1.97M | 1.94M | 1.93M | (4.22M) |
| Total Non-current Assets | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M |
| Total Assets | 194.54M | 155.27M | 144.03M | 92.17M | 150.93M |
| Account Payables | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.91M | 0 | 0 | 1K | 0 |
| Total Current Liabilities | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1 | 30M | 0 | 0 |
| Total Non-current Liabilities | 0 | 16M | 44.76M | 13.42M | 11.99M |
| Total Liabilities | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M |
| Common Stock | 70.36K | 70.47K | 71K | 71K | 130K |
| Retained Earnings | (171.36M) | (225.53M) | (277.87M) | (304.3M) | (321.71M) |
| Accumulated OCI | 0 | (42.19K) | 0 | (35K) | (202K) |
| Other Stockholders Equity | 0 | (1) | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M |
| Total Debt | 0 | 16.54M | 16M | 14.76M | 13.42M |
| Net Debt | (187.8M) | (28.33M) | (11.04M) | (11.55M) | 266K |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.